Cryoprecipitate

Global Rare Hemophilia Factors (I, II, VII) Market Size, Share & Trends Analysis Report 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 27, 2023
Health, Genetics, FDA, Child, Plasma, Second Continental Congress, Orphan Drug Act of 1983, Health care, Haemophilia, ODA, Hand, Treatment, Congress, Prevalence, VII, Coagulation factor VII, Personal protective equipment, Coagulation, Infection, Quality of life, Growth, COVID-19, Factor VII deficiency, Patient, Diagnosis, Speciality chemicals, Pharmaceutical industry, Tisagenlecleucel, Safety, Cryoprecipitate

The "Rare Hemophilia Factors Market Size, Share & Trends Analysis Report By Type (Factor I, Factor II, Factor VII), By Treatment (Factor Concentrates, Fresh Frozen Plasma, Cryoprecipitate), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rare Hemophilia Factors Market Size, Share & Trends Analysis Report By Type (Factor I, Factor II, Factor VII), By Treatment (Factor Concentrates, Fresh Frozen Plasma, Cryoprecipitate), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global rare hemophilia factors market is poised for substantial growth, targeting a USD 499.5 million market size by 2030, accompanied by a noteworthy compound annual growth rate (CAGR) of 6.9% from 2023 to 2030.
  • Prophylactic treatment is recommended for individuals with severe rare hemophilia factor disorders to prevent bleeding episodes and enhance their quality of life.
  • This intensified focus on patient safety measures is expected to have enduring benefits for rare hemophilia factor administration.

Cerus Corporation Announces Follow-on Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate

Retrieved on: 
Monday, June 5, 2023
Other Defense, FDA, Health Technology, Contracts, White House, Federal Government, Other Health, General Health, Medical Devices, Defense, Hospitals, Public Policy, Government, Military, Biotechnology, Health, Medical Supplies, Bleeding, U.S. Department of Defense Strategy for Operating in Cyberspace, United States Department of Defense, Survival, Temperature, Military personnel, IBAS, Corporation, Blood transfusion, Patient, CERS, Trauma, Death, Cryoprecipitate, Pharmaceutical industry, Cerus Corporation

Cerus’ LyoCryo product is being designed for shelf stability, rapid availability, and portability, enabling administration to patients in remote environments with the aim of increasing survival from traumatic injury bleeding.

Key Points: 
  • Cerus’ LyoCryo product is being designed for shelf stability, rapid availability, and portability, enabling administration to patients in remote environments with the aim of increasing survival from traumatic injury bleeding.
  • Optimizing survival and recovery of military personnel with combat-related injury is a priority for the Army’s Combat Casualty Care Research Program.
  • For civilians, trauma with massive bleeding is the leading cause of death for people under the age of 45 years in the U.S.
  • We are gratified by the DoD’s decision to provide additional funding for this important project,” stated Dr. Laurence Corash, Cerus’ chief scientific officer and co-founder.

Cerus Corporation to Participate in Upcoming Investor Conferences

Retrieved on: 
Friday, November 4, 2022
Biotechnology, Health, Clinical Trials, Medical Devices, Corporation, Hospital, FDA, Conference, Bleeding, Cryoprecipitate, Nasdaq, Plasma, CERS, Lotte New York Palace Hotel, EST, Patient, Factor, Pharmaceutical industry, Hotel, Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Cerus Corporation (Nasdaq: CERS) announced today that Vivek Jayaraman, Cerus chief operating officer, is scheduled to participate in two conferences:

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that Vivek Jayaraman, Cerus chief operating officer, is scheduled to participate in two conferences:
    The Stifel 2022 Healthcare Conference on Wednesday, November 16th at 1:50 p.m. EST, at the Lotte New York Palace Hotel.
  • To listen to webcasts of these presentations, please visit the investor relations section of Cerus website at: ir.cerus.com.
  • Cerus Corporation is dedicated solely to safeguarding the worlds blood supply and aims to become the preeminent global blood products company.
  • INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Cerus Corporation Announces Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate

Retrieved on: 
Wednesday, November 2, 2022
Biotechnology, Defense, Pharmaceutical, Medical Supplies, Contracts, General Health, Health, FDA, Cryoprecipitate, CERS, Survival, Plasma, Blood transfusion, Food and Drug Administration, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Hospital, Bleeding, Nasdaq, Program, CE, Technology, United States Department of Defense, Factor, Temperature, Trauma, FDA, Patient, Death, Military personnel, Corporation, IBAS, Pharmaceutical industry, Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Optimizing survival and recovery of military personnel with combat-related injury is a priority for the Armys Combat Casualty Care Research Program.

Key Points: 
  • Optimizing survival and recovery of military personnel with combat-related injury is a priority for the Armys Combat Casualty Care Research Program.
  • For civilians, trauma with massive bleeding is the leading cause of death for people under the age of 45 years in the U.S.
  • Since 2019, Cerus has been working to develop a lyophilized, pathogen reduced cryoprecipitate product and has advanced this program through several important development milestones, including product feasibility.
  • Cerus Corporation is dedicated solely to safeguarding the worlds blood supply and aims to become the preeminent global blood products company.

Cerus Corporation Announces Health Canada Approval for INTERCEPT Blood System for Platelets with Seven-Day Storage

Retrieved on: 
Tuesday, November 1, 2022
Biotechnology, Medical Devices, Hospitals, Health, Medical Supplies, Cryoprecipitate, CERS, Plasma, Health, Time, Hospital, Bleeding, Blood, Nasdaq, CE, Platelet, Collection, Adoption, Health Canada, B cell, Transfusion medicine, Factor, FDA, CBS, Patient, Corporation, Pharmaceutical industry, Medical device, Blood product, Society of Spanish Researchers in the United Kingdom (SRUK/CERU), Canadian Blood Services

Cerus Corporation (Nasdaq:CERS) today announced it has received approval from Health Canada to extend the storage of platelets treated with the INTERCEPT Blood System from five days to seven days from the time of collection, joining other territories where INTERCEPT platelets are approved for seven-day storage.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) today announced it has received approval from Health Canada to extend the storage of platelets treated with the INTERCEPT Blood System from five days to seven days from the time of collection, joining other territories where INTERCEPT platelets are approved for seven-day storage.
  • We look forward to working with Canadian Blood Services to realize these benefits for patients in Canada, Ms. Moore concluded.
  • The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components.
  • INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Cerus Corporation to Release Third Quarter 2022 Financial Results on November 3, 2022

Retrieved on: 
Thursday, October 20, 2022
Medical Supplies, Medical Devices, Health, General Health, Cardiology, Biotechnology, Bleeding, LinkedIn, Webcast, Investor relations, Patient, Hospital, Nasdaq, Company, Cryoprecipitate, Factor, Corporation, CE, Plasma, FDA, CERS, Online shopping, Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2022 financial results will be released on Thursday, November 3, 2022, after the close of the stock market.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2022 financial results will be released on Thursday, November 3, 2022, after the close of the stock market.
  • ET that afternoon, during which management will discuss the Companys financial results and provide a general business overview and outlook.
  • To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com.
  • Cerus Corporation is dedicated solely to safeguarding the worlds blood supply and aims to become the preeminent global blood products company.

Cerus Corporation Announces Workshop and Abstracts at the 2022 AABB Annual Meeting

Retrieved on: 
Monday, September 26, 2022
Biotechnology, General Health, Pharmaceutical, Health, Transfusion medicine, Bleeding, FDA, EDT, Corporation, Thrombin, LinkedIn, Patient, Cryoprecipitate, 2021 Essex County Council election, CE, Nasdaq, CERS, Hospital, Factor, Plasma, Online shopping, Medical device, Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2022 AABB Annual Meeting, taking place in Orlando, FL from October 1 through October 4.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2022 AABB Annual Meeting, taking place in Orlando, FL from October 1 through October 4.
  • This years AABB Annual Meeting attracts individuals and institutions from around the globe involved in the fields of transfusion medicine and biotherapies.
  • The following is a select list of presentations and abstracts of interest for Cerus.
  • Cerus Corporation is dedicated solely to safeguarding the worlds blood supply and aims to become the preeminent global blood products company.

Cerus Corporation Acknowledges Growing Monkeypox Outbreak and Public Health Emergency

Retrieved on: 
Friday, August 12, 2022
Medical Devices, Infectious Diseases, Hospitals, Health Technology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, FDA, Monkeypox, Risk, Technology, Hospital, Public health emergency, CE, Cryoprecipitate, Office of Inspector General, U.S. Department of Health and Human Services, Plasma, Patient, Bleeding, Factor, U.S. Department of Defense Strategy for Operating in Cyberspace, Infection, Corporation, Vaccinia, Virus, Uncertainty, CERS, World Blood Donor Day, Nasdaq, LinkedIn, TTID, Smallpox, Vaccine, Society of Spanish Researchers in the United Kingdom (SRUK/CERU), West Nile virus, Chikungunya

Cerus Corporation (Nasdaq: CERS) acknowledges the U.S. Department of Health and Human Services declaration of monkeypox as a national Public Health Emergency.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) acknowledges the U.S. Department of Health and Human Services declaration of monkeypox as a national Public Health Emergency.
  • Currently, more than 10,000 cases of monkeypox have been reported across the U.S., and over 30,000 cases have been confirmed globally.
  • For nearly two decades, the INTERCEPT Blood System for platelets and plasma has been shown to inactivate a broad spectrum of pathogens.
  • Cerus Corporation is dedicated solely to safeguarding the worlds blood supply and aims to become the preeminent global blood products company.

Cerus Corporation to Release Second Quarter 2022 Financial Results on August 4, 2022

Retrieved on: 
Thursday, July 21, 2022
Biotechnology, General Health, Medical Devices, Health, Medical Supplies, Corporation, Cryoprecipitate, Bleeding, Hospital, Factor, Investor relations, Webcast, CE, FDA, Company, Patient, LinkedIn, Nasdaq, CERS, Plasma, Online shopping, Medical device, Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2022 financial results will be released on Thursday, August 4, 2022, after the close of the stock market.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2022 financial results will be released on Thursday, August 4, 2022, after the close of the stock market.
  • ET that afternoon, during which management will discuss the Companys financial results and provide a general business overview and outlook.
  • To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com.
  • Cerus Corporation is dedicated solely to safeguarding the worlds blood supply and aims to become the preeminent global blood products company.

Cerus Corporation Announces Appointment of Hua Shan, MD, PhD to Board of Directors

Retrieved on: 
Tuesday, July 5, 2022
Medical Supplies, Health, Hospitals, Health Technology, Other Health, Biotechnology, FDA, Board of directors, Cryoprecipitate, Pathology, Patient, LinkedIn, Stanford University Medical Center, University, Mount Hua, Company, Plasma, Chairperson, Corporation, Bleeding, CE, Stanford University, Factor, Medical director, Doctor of Philosophy, Nasdaq, Human, Medical school, Hospital, Board, Associate, Johns Hopkins University, CERS, Knowledge, Medical University of South Carolina, Director, Transfusion medicine, Medical device, MD, Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Cerus Corporation (Nasdaq: CERS) today announced the appointment of Hua Shan, MD, PhD, Professor of Pathology and Medical Director, Transfusion Medicine Service at Stanford Medical Center to its Board of Directors.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) today announced the appointment of Hua Shan, MD, PhD, Professor of Pathology and Medical Director, Transfusion Medicine Service at Stanford Medical Center to its Board of Directors.
  • We are pleased to welcome Dr. Shan to Cerus Board of Directors, said Daniel Swisher, Chair of the Board.
  • I am delighted to be joining the Board of Directors at Cerus during this exciting time in the Companys history, said Dr. Shan.
  • Cerus Corporation is dedicated solely to safeguarding the worlds blood supply and aims to become the preeminent global blood products company.